Advanced Solid Tumor, BRAF V600 Mutation
Conditions
Keywords
Melanoma, Colorectal Cancer, Glioblastoma, Cholangiocarcinoma, Non-small Cell Lung Cancer, Thyroid Cancer, Ovarian Cancer
Brief summary
This is a Phase I, First-In-Human, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult patients with locally advanced or metastatic solid tumors who have no effective standard treatment options available, as monotherapy in patients with documented BRAF V600 mutation, or in combination with cobimetinib (Cotellic®) in adult patients who have documented BRAF mutation and progressive disease or intolerance to at least one prior line of systemic therapy.
Detailed description
This is a Phase I, First-In-Human, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult patients with locally advanced or metastatic solid tumors who have no effective standard treatment options available, as monotherapy in patients with documented BRAF V600 mutation, or in combination with cobimetinib (Cotellic®) in adult patients who have documented BRAF mutation and progressive disease or intolerance to at least one prior line of systemic therapy. The primary objectives of this study are to determine the Maximum Tolerated Dose (MTD) and/or the Recommended Phase II Dose (RP2D) of both single agent and combination treatment and to assess the safety and tolerability of ABM-1310 as a monotherapy and in combination. Study consists of three Parts: Part A: The starting dose of ABM-1310 is 25 mg po bid, and dose escalation will be guided by a 3+3 design. ABM-1310 will be administered twice daily on a continuous schedule. Each treatment cycle consists of 28 days. Part B: The starting dose of ABM-1310 will be a dose below the MTD that has been demonstrated to be safe in Part A Monotherapy. A classic 3+3 design will guide the dose escalation. At each dose level, ABM-1310 will be administered in combination with 60 mg cobimetinib (Cotellic ®) once daily (qd) for the first 21 days of each 28-day treatment cycle. Part C: * In C-1 (Monotherapy - Primary CNS Tumors) and C-2 (Monotherapy - Advanced or Metastatic solid tumors excluding Primary CNS tumors with or without Brain Metastasis), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met. * In C-3 (Combination therapy - Advanced/Metastatic Solid Tumors including Primary CNS Tumors but excluding Melanoma with Brain Metastsis) and C-4 (Combination therapy - Melanoma with Brain Metastasis), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B, in combination with cobimetinib (Cotellic®) 60 mg administered the first 21 days of each 28-day treatment cycle until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met. Dose limiting toxicity (DLT) will be evaluated and managed per the pre-defined DLT criteria and rules specified in the protocol. MTD and/or RP2D will be confirmed in a dose confirmation cohort.
Interventions
DRUGABM-1310
Part A: Starting dose at 25 mg by mouth twice daily. Part B: Starting dose at a dose below the MTD( Maximum Tolerated Dose) that has been demonstrated to be safe in Part A. Part C-1 and C-2: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met. Part C-3 and C-4: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.
DRUGCobimetinib
Part B: orally administered once daily. Part C-3 and C-4: Continuous once daily oral dose from Part B, administered the first 21 days of each 28-day treatment cycle until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met. Dose formulation is 60 mg capsules.
Sponsors
ABM Therapeutics Corporation
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Study consists of Three Parts: Part A: ABM-1310 Dose Escalation and MTD/RP2D Dose Confirmation Part B: Combination agent (ABM-1310 and cobimetinib (Cotellic®)) Dose Escalation and MTD/RP2D Dose Confirmation Part C: Dose Expansion (ABM-1310 Monotherapy/Combination Therapy)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male and female subjects age 18 years and older who are able to sign informed consent and to comply with the protocol 2. Patients with histologically or cytologically-documented, locally advanced, or metastatic solid tumor malignancy that has either (a) progressed on at least one line of prior standard systemic therapy, (b) for which no standard therapy exists, or (c) standard therapy is not considered appropriate by the patient or treating physician. There is no limit to the number of prior treatment regimens * Part A: Patients with advanced or metastatic solid tumors with documentation of positive BRAF V600E mutation, or any other BRAF V600 mutation is required for enrollment * Part B: Patients with advanced or metastatic solid tumors with documentation of any BRAF mutation. * Part C: 1. C-1: Patients with primary central nervous system (CNS) tumors and documentation of positive BRAF V600 mutation 2. C-2: Patients with advanced or metastatic solid tumors and documentation of positive BRAF V600 mutation excluding primary CNS tumor 3. C-3: Patients with advanced or metastatic solid tumors and documentation of positive BRAF mutation including primary CNS tumors but excluding melanoma with brain metastasis 4. C-4: Patients with melanoma with brain metastasis and documentation of positive BRAF mutation Patients with active or stable brain metastasis that are asymptomatic, or that are symptomatic treated with a total daily dose of no more than 4 mg of dexamethasone (or equivalent) that is stable or tapering for at least 2 weeks prior to first treatment are eligible for enrollment. Patients with neurologic signs and symptoms who are not being treated with steroids are eligible and should have no experience of seizure within 2 weeks prior to first treatment. 3. Must have at least one measurable lesion as defined by RECIST V1.1 criteria for solid tumors or the RANO criteria for primary CNS tumors, such as gliomas. * For solid tumor with Brain Metastases: * Measurable brain lesions that are 0.5 - 3 cm in longest diameter as defined by the modified RECIST V1.1 criteria are allowed. * Brain lesion size \> 3 cm is not eligible. 4. ECOG performance status of 0 or 1 or Karnofsky performance status of ≥ 70 5. Adequate organ function confirmed at screening and within 28 days of initiating treatment, as evidenced by: * Absolute Neutrophil Count (ANC) ≥ 1.0 x 10\^9/L * Hemoglobin (Hgb) ≥ 9 g/dl * Platelets (Plt) ≥ 100 x 10\^9/L * AST/ALT ≤ 2.5 x Upper Limit of Normal (ULN) or ≤ 5.0 x ULN if liver metastases are present * Total bilirubin ≤ 1.5 x ULN, or direct bilirubin \<ULN for patients with total bilirubin levels \>1.5 ULN * Serum creatinine \<1.5 x ULN or measured or calculated (per institutional standard) creatinine clearance of \> 60 mL/min. 6. Negative pregnancy test within 72 hours before starting study treatment in all pre-menopausal women and women \<12 months after the onset of menopause 7. Male and female subjects must agree to take sufficient contraceptive methods to avoid pregnancy before first dose of study treatment, during the study, and for at least 3 months after ceasing study treatment
Exclusion criteria
1. Women who are pregnant or breast-feeding 2. Women of child-bearing potential (WOCBP) who does not use adequate birth control 3. Patients with any hematologic malignancy. This includes leukemia, lymphoma, and multiple myeloma 4. Have a second primary malignancy that, in the judgment of the investigator, may affect the interpretation of results 5. Patients with carcinomatous meningitis (leptomeningeal disease (LMD)) 6. Patients with history of stroke ≤ 6 months prior to starting study drug 7. Patients who have had an experience of seizure within 14 days prior to first treatment 8. Impaired cardiac function or clinically significant cardiac diseases, including but not limited to any of the following: * Left Ventricular Ejection Fraction (LVEF) \< 45% as determined by MUGA scan or ECHO * Congenital long QT syndrome * QTcF ≥ 450 msec (mean) on screening (Triplicate 12-Lead ECG) * Unstable angina pectoris ≤ 6 months prior to starting study drug * Acute myocardial infarction ≤ 6 months prior to starting study drug * Use of pacemaker 9. Patients with * Unresolved diarrhea ≥ CTCAE Grade 2, or * Impairment of gastrointestinal (GI) function, or * GI disease or conditions that may significantly alter the absorption of ABM-1310 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) 10. Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g., uncontrolled hypertriglyceridemia \[triglycerides \>500 mg/dL\], active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol 11. Extensive prior radiotherapy to more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation within 5 years 12. Patients who have received chemotherapy, targeted therapy or immunotherapy ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy, except: * ≤ 6 weeks for nitrosourea or mitomycin-C * ≤ 5 half-lives or 2 weeks for small molecule inhibitor treatment, whichever is longer 13. Patients who have received wide field radiotherapy ≤ 4 weeks, limited field radiation for palliation ≤ 2 weeks, prior whole-brain radiotherapy (WBRT) ≤ 4 weeks or stereotactic radiosurgery (SRS) ≤ 2 weeks (one week for patients with primary CNS tumor such as GBM or with brain metastasis) prior to starting study drug or patients who have not recovered from side effects of such therapy 14. Patients who have undergone major surgery ≤ 4 weeks in general prior to starting study drug or who have not recovered from side effects of such therapy. However, a minimum of 2 weeks recovery time from major surgery prior to starting study drug is acceptable if in investigator's opinion the patient has recovered from surgery. 15. Patients who are currently receiving treatment with therapeutic doses of warfarin sodium or any other coumarin-derivative anticoagulants 16. Patients who have received systemic corticosteroids ≤ 2 weeks prior to starting study drug or who have not recovered from the side effects of such treatment. Therapeutic doses of corticosteroids up to 4 mg/day of dexamethasone, or equivalent are allowed. Note: Patients that are taking replacement doses of steroids are eligible 17. Patients who are currently receiving treatment with medication that has known risk to prolong the QT interval, and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug 18. Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory; patients with well controlled HIV might be enrolled per investigator's discretion) 19. Known history of active infection with Hepatitis B (e.g., HBsAg reactive), or Hepatitis C (e.g., S RNA (qualitative) is detected) 20. History of alcohol or drug abuse ≤ 3 months prior to first dose 21. Has a history or current evidence of any condition, therapy, or laboratory abnormality that, in the opinion of the investigator, might confound the results of the trial, interfere with the patient's participation and compliance in the trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | Up to study discontinuation (an average of 1 year) | Safety and tolerability of ABM-1310 as a monotherapy and in combination therapy at Part A and Part B's Recommended Phase 2 dose (RP2D) in Part C |
| Number of participants with abnormal laboratory values | Up to study discontinuation (an average of 1 year) | Safety and tolerability of ABM-1310 as a monotherapy and in combination therapy at Part A and Part B's Recommended Phase 2 Dose (RP2D) in Part C |
| Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) | End of Cycle 1 (each cycle is 28 days) or up to treatment discontinuation (an average of 6 months) | Determine Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) as a monotherapy and in combination therapy in Part A and Part B |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area under the concentration time curve (AUC) | Up to Day 1 of Cycle 2 (each cycle is 28 days) | Pharmacokinetic (PK) profile of ABM-1310 as a single agent and in combination therapy |
| Maximum plasma concentration (Cmax) | Up to Day 1 of Cycle 2 (each cycle is 28 days) | Pharmacokinetic (PK) profile of ABM-1310 as a single agent and in combination therapy |
| Steady-state concentration (Css) | Up to Day 1 of Cycle 2 (each cycle is 28 days) | Pharmacokinetic (PK) profile of ABM-1310 as a single agent and in combination therapy |
| Time to maximum plasma concentration (Tmax) | Up to Day 1 of Cycle 2 (each cycle is 28 days) | Pharmacokinetic (PK) profile of ABM-1310 as a single agent and in combination therapy |
| Half-life (T1/2) | Up to Day 1 of Cycle 2 (each cycle is 28 days) | Pharmacokinetic (PK) profile of ABM-1310 as a single agent and in combination therapy |
| Disease Control Rate (DCR) | Up to study discontinuation (an average of 1 year) | Preliminary efficacy of ABM-1310 as a single agent and in combination therapy |
| Duration of Response (DOR) | Up to study discontinuation (an average of 1 year) | Preliminary efficacy of ABM-1310 as a single agent and in combination therapy |
| Progression free survival (PFS) | Up to study discontinuation (an average of 1 year) | Preliminary efficacy of ABM-1310 as a single agent and in combination therapy |
| Overall Survival (OS) | Up to study discontinuation (an average of 1 year) | Preliminary efficacy of ABM-1310 as a single agent and in combination therapy |
| Time to Response (TTR) | Up to study discontinuation (an average of 1 year) | Preliminary efficacy of ABM-1310 as a single agent and in combination therapy |
| Objective Response Rate (ORR) | Up to study discontinuation (an average of 1 year) | Preliminary efficacy of ABM-1310 as a single agent and in combination therapy |
| Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | Up to 30 days from treatment discontinuation | Safety and tolerability of ABM-1310 as a single agent and in combination therapy in Part A and Part B |
| Number of participants with abnormal laboratory values | Up to 30 days from treatment discontinuation | Safety and tolerability of ABM-1310 as a single agent and in combination therapy in Part A and Part B |
Other
| Measure | Time frame | Description |
|---|---|---|
| Exploratory preliminary efficacy in patients by types of BRAF V600 mutation | Up to study discontinuation (an average of 1 year) | Preliminary efficacy of ABM-1310 as a single agent and in combination therapy |
| Identification of major metabolite of ABM-1310 in patients who receive ABM-1310 monotherapy in Part C | Up to study discontinuation (an average of 1 year) | Tests to identify major metabolite of ABM-1310 by a central lab on the post-dose blood samples from patients who receive ABM-1310 monotherapy in Part C |
Countries
United States
Outcome results
None listed